NO950660L - Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav - Google Patents

Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav

Info

Publication number
NO950660L
NO950660L NO950660A NO950660A NO950660L NO 950660 L NO950660 L NO 950660L NO 950660 A NO950660 A NO 950660A NO 950660 A NO950660 A NO 950660A NO 950660 L NO950660 L NO 950660L
Authority
NO
Norway
Prior art keywords
hla
mage
gene
presented
well
Prior art date
Application number
NO950660A
Other languages
English (en)
Other versions
NO950660D0 (no
Inventor
Thierry Boon-Falleur
Pierre Van Der Bruggen
Etienne De Plaen
Christophe Lurquin
Catia Traversari
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,334 external-priority patent/US5405940A/en
Priority claimed from US08/037,230 external-priority patent/US6235525B1/en
Priority claimed from PCT/US1993/008157 external-priority patent/WO1994005304A1/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO950660D0 publication Critical patent/NO950660D0/no
Publication of NO950660L publication Critical patent/NO950660L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Et nonapeptid avledet fra tumor-rejeksjonsantigen- forstadiget som kodes av genet MAGE-3. Dette nonapeptid presenteres ved hjelp av HLA-molekyler HLA-A1. De resul- terende komplekser identifiseres ved hjelp av cytolytiske T-celler. Slik gjenkjennelse kan benyttes i diagnose eller terapeutisk.
NO950660A 1992-08-31 1995-02-22 Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav NO950660L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/938,334 US5405940A (en) 1992-08-31 1992-08-31 Isolated nonapeptides derived from MAGE genes and uses thereof
US08/037,230 US6235525B1 (en) 1991-05-23 1993-03-26 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US08/073,103 US5462871A (en) 1992-08-31 1993-06-07 Isolated nucleic acid molecules which encode MAGE derived nonapeptides
PCT/US1993/008157 WO1994005304A1 (en) 1992-08-31 1993-08-30 Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof

Publications (2)

Publication Number Publication Date
NO950660D0 NO950660D0 (no) 1995-02-22
NO950660L true NO950660L (no) 1995-02-24

Family

ID=27365171

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950660A NO950660L (no) 1992-08-31 1995-02-22 Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav

Country Status (3)

Country Link
US (1) US5462871A (no)
EP (1) EP1361271B1 (no)
NO (1) NO950660L (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
WO1995004542A1 (en) * 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
CA2201327A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
US5759783A (en) * 1995-03-14 1998-06-02 Ludwig Institute For Cancer Research Method of screening for cancer by detecting messenger RNA for a MAGE-XP gene
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5858665A (en) * 1996-07-25 1999-01-12 Navix, Inc. Homogeneous diagnostic assay method utilizing simultaneous target and signal amplification
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
JP4540033B2 (ja) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および／または増強する方法
WO2001053833A1 (en) * 2000-01-20 2001-07-26 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
US7098008B2 (en) * 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
KR100374423B1 (ko) * 2000-04-25 2003-03-28 주식회사 아이씨엔지 다수의 ｍａｇｅ 아형 또는 ｇａｇｅ 아형을 인식하는암진단용 프라이머
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US6492120B1 (en) 2000-11-02 2002-12-10 University Of Maryland Nucleic acid hybridization assay utilizing tricyclic target and signal amplification
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
EP2292638A3 (en) 2002-09-27 2011-03-23 Ludwig Institute For Cancer Research MAGE-C2 antigenic peptides and uses thereof
CA2510238A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Cancer treatment using vaccine and high-dose cytokine
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
ATE545708T1 (de) * 2005-11-14 2012-03-15 Univ Laval Krebsantigen mage-a9 und verwendungen davon
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Also Published As

Publication number Publication date
EP1361271A2 (en) 2003-11-12
EP1361271A3 (en) 2004-04-21
US5462871A (en) 1995-10-31
NO950660D0 (no) 1995-02-22
EP1361271B1 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
NO950660L (no) Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav
FI950887A0 (fi) MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
Ferreira et al. Some interactional variables in normal and abnormal families.
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
DK0759032T3 (da) Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
CA970692A (en) METHODS OF INHIBITING THE ACTIVITY OF TESTOSTERONE 5.alpha.-REDUCTASE
CA959586A (en) Process for the reduction of the biochemical oxygen demand of sewage, and for the recovery of the inherent protein
Bexell Liturgins teologi hos UL Ullman.
Vorster The rhetorical situation of the letter to the Romans: An interactional approach.
SU656475A3 (ru) Лабораторный смеситель
CA972350A (en) 1,2-METHYLENE-17.alpha.-ACYLOXY(OR IMPROVED HYDROXY)-9.beta.,10.alpha.-STEROID COMPOUNDS OF THE PREGNANE SERIES, PHARMACEUTIC PREPARATIONS OF THE BASIS OF THE NOVEL COMPOUNDS AND METHODS OF PRODUCING SAID COMPOUNDS AND PREPARATIONS
NO963917L (no) Isolerte, MAGE-3-avledete peptider som komplekserer med HLA-A2-molekyler, samt anvendelser derav
USD166698S (en) orloff
Robbins Objectionable aspects of" cults": Rhetoric and reality.
CH551400A (de) Verfahren zur herstellung von 4-chlor-1, 2(alpha)-methylen(delta)4,6-pregnadien-17(alpha)-ol-3,20-dion bzw. dessen 17estern.
CA969175A (en) 6.alpha.,9.alpha.-DIFLUOROSTEROIDS OF THE PREGNANE SERIES AND PROCESSES FOR THEIR MANUFACTURE
Schaub They
CA498696A (en) 8,17,21-trihydroxy-4-pregnene-3,20 dione
CA689986A (en) 11.alpha.,17.alpha.,21-TRIHYDROXY-4-PREGNENE-3,20-DIONE ESTERS
CA832440A (en) PROCESS FOR THE MANUFACTURE OF 1,2.alpha.-METHYLENE-19-NOR-STEROIDS
CA863337A (en) .DELTA.1,4-PREGNADIENE-17.alpha.,21-DIOL-3,11,20-TRIONE
CA646690A (en) SYNTHESIS OF .DELTA.1,4-PREGNADIENE-17.alpha.,21-DIOL-3,20-DIONE
CA912548A (en) NOVEL PROCESSES FOR THE PREPARATION OF 7.beta., 17.alpha.-DIMETHYL-17-HYDROXYANDROST-4-EN-3-ONE AND ITS ACYLATES
CA822666A (en) 9.beta.,10.alpha.-STEROIDS AND METHODS OF PRODUCING THE SAME